Blocking connexin43 expression reduces inflammation and improves functional recovery after spinal cord injury

Mol Cell Neurosci. 2008 Oct;39(2):152-60. doi: 10.1016/j.mcn.2008.06.005. Epub 2008 Jun 19.

Abstract

After traumatic CNS injury, a cascade of secondary events expands the initial lesion. The gap-junction protein connexin43 (Cx43), which is transiently up-regulated, has been implicated in the spread of 'bystander' damage. We have used an antisense oligodeoxynucleotide (asODN) to suppress Cx43 up-regulation in two rat models of spinal cord injury. Within 24 h of compression injury, rats treated with Cx43-asODN scored higher than sense-ODN and vehicle-treated controls on behavioural tests of locomotion. Their spinal cords showed less swelling and tissue disruption, less up-regulation of astrocytic GFAP, and less extravasation of fluorescently-labelled bovine serum albumin and neutrophils. The locomotor improvement was sustained over at least 4 weeks. Following partial spinal cord transection, Cx43-asODN treatment reduced GFAP immunoreactivity, neutrophil recruitment, and the activity of OX42(+) microglia in and around the lesion site. Cx43 has many potential roles in the pathophysiology of CNS injury and may be a valuable target for therapeutic intervention.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • CD11b Antigen / metabolism
  • Capillary Permeability / drug effects
  • Capillary Permeability / physiology
  • Connexin 43 / antagonists & inhibitors
  • Connexin 43 / metabolism*
  • Disease Models, Animal
  • Down-Regulation / drug effects
  • Down-Regulation / physiology*
  • Glial Fibrillary Acidic Protein / metabolism
  • Inflammation / drug therapy*
  • Inflammation / etiology
  • Inflammation / metabolism
  • Inflammation / pathology
  • Locomotion / drug effects
  • Male
  • Microglia / drug effects
  • Oligodeoxyribonucleotides, Antisense / pharmacology
  • Oligodeoxyribonucleotides, Antisense / therapeutic use*
  • Rats
  • Rats, Sprague-Dawley
  • Recovery of Function / drug effects
  • Recovery of Function / physiology*
  • Spinal Cord Injuries / complications*
  • Spinal Cord Injuries / drug therapy
  • Spinal Cord Injuries / pathology
  • Time Factors

Substances

  • CD11b Antigen
  • Connexin 43
  • Glial Fibrillary Acidic Protein
  • Oligodeoxyribonucleotides, Antisense